Axsome Therapeutics, Inc.
NASDAQ:AXSMBiotechnology
+$0.25 today
- Market cap
- $7.05B
- Beta
- 0.60
- P/E (TTM)
- -68.6
- EPS (TTM)
- -$3.68
Volume 0.74M
Average 0.72M
AXSM Total Debt
Short-term and long-term borrowings combined.
Axsome Therapeutics, Inc.NASDAQ: AXSM
Total Debt · Q2 FY2026 · quarter ended Jun 2026
Total debt broadly unchanged from a year ago
Total debt stood at $219.21M at the end of Q2 FY2026, up 0.9% from a year earlier and down 0.3% from the prior quarter. Over 3 fiscal years it compounded at +36.6% a year.
Context
- Total debt amounted to 28.8% of total assets at the end of Q2 FY2026, down 5.2 pp from a year earlier.
- Total debt increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps rising in the next quarterly balance sheet after a +0.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 241.3M USD
- Year-over-year change
- +25.1%
- 4-year CAGR
- +48.4%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 241.3M | +25.1% |
| FY2024 | 2024-12-31 | 192.96M | +3.5% |
| FY2023 | 2023-12-31 | 186.37M | +96.8% |
| FY2022 | 2022-12-31 | 94.68M | +90.5% |
| FY2021 | 2021-12-31 | 49.71M | — |
Total Debt vs competitors
How AXSM compares with its peers on the latest reported figures
- AXSM's Jun 2026 total debt of $219.21M is the 3rd highest of the 11 companies compared; the peer median is $19.15M.
- Its year-over-year change of +0.9% is the 4th highest of 10, against a peer median of -9.2%.
- Total debt amounts to 28.8% of total assets for AXSM, versus a peer median of 2.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $1.08B | -80.1% | -2.3% | 9.0% | |
| Sep 2026 | $392.3M | -8.4% | +16.5% | 7.0% | |
| Jun 2026 | $219.21M | +0.9% | +36.6% | 28.8% | |
| Jun 2026 | $40.17M | +26.4% | -54.8% | 2.8% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $36.66M | -9.2% | — | 3.4% |
| Jun 2026 | $27.51M | -40.9% | -15.2% | 2.4% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $10.8M | +37.8% | +3.2% | 2.2% |
| Sep 2026 | $6.01M | -27.8% | -8.7% | 0.5% | |
| Sep 2026 | $732K | +67.9% | -68.4% | 0.1% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $410K | -56.3% | -61.6% | 0.3% |
| Dec 2025 | $0 | — | — | 0.0% | |
| Peer median (excluding AXSM) | $19.15M | -9.2% | -12.0% | 2.3% | |
Competitors are the stored peer set for AXSM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 86.47M | 200.84M | 386.19M | 315.35M | 322.93M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 37.7M | 94.82M | 142M | 224.46M |
| Inventory | 0 | 4.32M | 15.14M | 15.73M | 27.94M |
| Other Current Assets | 0 | 2.78M | 8.12M | 11.98M | 13.65M |
| Total Current Assets | 86.52M | 245.64M | 504.26M | 485.06M | 588.99M |
| Property, Plant & Equipment (Net) | 944.01K | 1.14M | 7.62M | 5.97M | 20.86M |
| Goodwill | 0 | 10.31M | 12.04M | 12.04M | 12.04M |
| Intangible Assets | 0 | 59.66M | 53.29M | 46.89M | 40.52M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 322.91K | 14.72M | 11.03M | 18.53M | 27.4M |
| Total Non-current Assets | 1.27M | 85.83M | 83.97M | 83.43M | 100.82M |
| Total Assets | 87.79M | 331.48M | 588.24M | 568.5M | 689.81M |
| Account Payables | 13.15M | 38.61M | 40.68M | 72M | 65.54M |
| Short-term Debt | 0 | 0 | 0 | 0 | 72.98M |
| Tax Payables | 0 | 0 | 0 | 960K | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.05M | 17.18M | 76.45M | 36.51M | 203.28M |
| Total Current Liabilities | 23.07M | 96.56M | 138.85M | 230.1M | 378.84M |
| Long-term Debt | 49.09M | 94.26M | 178.07M | 180.71M | 140.93M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 31.1M | 73.3M | 91.68M | 54.36M |
| Total Non-current Liabilities | 49.09M | 125.36M | 258.41M | 281.38M | 222.67M |
| Total Liabilities | 72.15M | 221.92M | 397.26M | 511.48M | 601.51M |
| Common Stock | 3.78K | 4K | 5K | 5K | 5K |
| Retained Earnings | (409.2M) | (596.33M) | (835.57M) | (1.12B) | (1.31B) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | (0) | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 15.63M | 109.56M | 190.98M | 57.02M | 88.3M |
| Total Debt | 49.71M | 94.68M | 186.37M | 192.96M | 241.3M |
| Net Debt | (36.76M) | (106.16M) | (199.82M) | (122.4M) | (81.64M) |
Axsome Therapeutics, Inc.
NASDAQ:AXSM
Intrinsic Alpha fair value
Locked
Current Price
$134.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.